Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA326519 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Establishment and Molecular Characterization of Glioblastoma Primary Cultures
| PRJNA257196 | ENA
Project description:Clinical and Molecular Characteristics of Congenital Glioblastoma Multiforme
| PRJNA147977 | ENA
Project description:Glioblastoma, the most frequent and malignant adult brain tumor has been extensively studied; yet no effective treatment exists. To overcome this dismal scenario, it is essential to improve preclinical biological models. This study aimed to establish and molecularly characterize glioblastoma primary cultures. Additionally, it intended to assess the efficacy of molecular-targeted therapies, in the presence of putative targeting cell lines. Five glioblastoma primary cultures were established exhibiting a diversity of chromosomal alterations by aCGH, with gain of chromosome 7 and loss of chromosome 10, 13 and 17p, the most frequent alterations. Mutation profiling by Ion Torrent and Sanger sequencing showed the present of hotspot mutations in TERT (4/5), TP53 (2/5) and RB, BRAF, PTEN and EGFR (1/5). A similar chromosomal and mutation pattern was observed in the primary cultures and matched frozen tumors. The MTS cell viability assay of the p.Gly598Val EGFR mutated cell line, revealed AST1306 as the most potent EGFR inhibitor, when compared with afatinib, erlotinib, or lapatinib. Herein, glioblastoma primary cultures were successfully established and molecularly characterized. Importantly, we showed that AST1306 inhibits EGFR mutated cells, suggesting that primary cultures are suitable in vitro models for glioblastoma biology and preclinical drugs studies. Two-color Agilent 8x60K array CGH (aCGH) was performed in 10 glioblastoma multiforme samples (CY3) and reference DNA (CY5). The 10 glioblastoma multiforme samples were: DNA extracted from 5 primary cultured cells; DNA of 5 primary tumors (matched with the 5 primary cell lines). Gender-matched commercial DNA of each case was used as control.
2016-07-01 | E-GEOD-59967 | biostudies-arrayexpress
Project description:A Cartes d'Identite des Tumeurs (CIT) project from the French National League Against Cancer (http://cit.ligue-cancer.net ) 25 glioblastoma multiforme tumors hybridized on Illumina SNP and Affymetrix gene expression arrays. Project leader : François DUCRAY (francois.ducray@chu-lyon.fr). CIT Analysis : Julien LAFFAIRE (laffairej@ligue-cancer.net). Note: PFS : progression-free survival, OS: Overall Survival,BCNU : Carmustine (chemotherapy agent). RESPONDER: if the patient has shown or not shown a response to the treatment (Bevacizumab (Avastin) plus Irinotecan). Progression during : If the disease has progressed (cancer relapse or patient's death); otherwise (patient is alive without relapse).
2013-01-15 | E-MTAB-951 | biostudies-arrayexpress
Project description:Histone modification and gene expression profiling in primary glioblastoma multiforme tumors
| PRJNA391756 | ENA
Project description:Primary cultures of glioblastoma multiforme (GBM) were isolated from samples provided as section of areas immediately adjacent to the region used for the histopathological diagnosis and cultured in defined media. Transcriptomic analysis was performed with high-quality RNA extracted from cells after early passages in cultures (<2 passages).
2018-06-01 | GSE83626 | GEO
Project description:Dendritic Cell Vaccine against Glioblastoma Multiforme Patients
| PRJNA106981 | ENA
Project description:Copy number analysis of human glioblastoma multiforme
| PRJNA112561 | ENA
Project description:DZNep-treated glioblastoma multiforme cancer stem cells
| PRJNA119483 | ENA